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Abstract
Background: Benign liver tumours represent a challenge in clinical management. There is consider-
able controversy with respect to the indications for surgery as the evidence for surgical treatment is
variable. The aim of this retrospective study was to analyse the indication and outcome after resection
of benign, solid liver lesions.
Methods: Data of 79 patients, who underwent liver resection between 2001 and 2012, were analysed
for demographic and outcome parameters.
Results: Thirty-eight patients with focal nodular hyperplasia (48%), 23 patients with haemangioma
(29%) and 18 patients with hepatocellular adenoma (23%) underwent a hepatic resection. A major hep-
atic resection was performed in 23 patients (29%) and a minor resection in 56 patients (71%). The
post-operative mortality rate was zero and the 30-day morbidity rate 13.9%. After a median follow-up
of 64 months, 75 patients (95%) were alive, and no patient had developed recurrent disease. Fifty-four
patients (68%) were pre-operatively symptomatic, of which, 87% had complete or partial relief of
symptoms after a liver resection. The incidence of symptoms increased with the lesions’ size.
Discussion: The management of benign liver lesions necessitates an individualized therapy within a
multidisciplinary, evidence-based, treatment algorithm. Resection of benign liver lesions can be per-
formed safely in well-selected patients without mortality and low post-operative morbidity.
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Introduction
There is considerable controversy with respect to the indica-
tion for a liver resection (LR) in patients with benign liver
lesions, and this is as a result of the heterogeneity of the
diseases.1 Benign liver lesions can be classified into (hyper-)
regenerative lesions (such as focal nodular hyperplasia and an
inflammatory pseudotumour) and neoplastic lesions (includ-
ing hepatocellular adenoma, haemangioma and angiomy-
olipoma). The widespread use and availability of cross-
sectional imaging has increased the detection of hepatic
lesions. The majority of so-called hepatic incidentalomas are
benign with a prevalence of up to 15% in the population.2
Thus, careful and accurate selection and investigation is
required to establish a precise diagnosis with a clear distinc-
tion between benign lesions and malignant tumours. In partic-
ular, being able to differentiate between hepatocellular
adenoma (HCA) (with all of its immunohistochemically
defined subtypes), well-differentiated hepatocellular carcinoma
(HCC) and focal nodular hyperplasia (FNH) is sometimes dif-
ficult.3 In the majority of patients, modern imaging studies
using liver-specific contrast agents have allowed precise diag-
nosis of the most common benign, solid liver lesions, such as
haemangioma and FNH.4 However, the nature of the lesion
remains uncertain 5–10% of patients. When the diagnosis of a
benign liver lesion is established, a team of hepato-biliary spe-
cialists (with the inclusion of a radiologist, pathologist, hepa-
tologist and a liver surgeon) must decide whether an
observational, interventional or a surgical approach is appro-
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priate. The treatment approaches for benign, solid liver lesions
are not based on the highest level of evidence. The clinical
decision-making process is heavily influenced by the reliability
of the diagnostic and the accurate assessment of the symp-
toms. In the case of a symptomatic patient, whether or not
the lesion is causing the symptoms has to be evaluated.
Should there be patients with inconclusive imaging results,
large lesions with an invasive and dislodging growth pattern,
signs of bleeding, or lesions that are highly susceptible to rup-
tures (e.g. lesions larger 5 cm), the contemporary hepato-
biliary advice is resection of the lesion. This is especially true
for HCA patients of the ß-catenin-mutated subtype in whom
the two major complications (such as bleeding and the risk of
malignant transformation) have to be avoided. However, it
has to be carefully evaluated whether or not the biological risk
posed by the lesion outweighs the risk of LR. Nowadays, a
strategy of a shared decision-making process involving the
treating physicians together with the patients should be
routine prior to surgery.
Here, the single-centre experience with patients undergoing
LR for benign, solid lesions is reported.
Patients and methods
Between 2001 and 2012, 2042 LRs were performed in the
Department of General, Visceral and Transplant Surgery,
University Hospital Heidelberg, Germany. Patients with con-
comitant resections as a result of other extrahepatic diseases
were excluded from the analysis. Informed consent was
obtained from all patients prior to surgical treatment. Data
collection and analysis were performed according to institu-
tional guidelines that conform to the ethical standards of the
Helsinki Declaration and was approved by the local ethics
committee (S390/2012).
The majority of patients were transferred to the centre on
the advice of their general practitioners after a period of obser-
vation during which, an exacerbation of the symptoms, an
increase in the size of the known benign liver lesions or the
presence of unclear liver lesions had been detected by routine
assessment for unspecified abdominal symptoms via ultra-
sonography or CT scan. All the patients were seen in an inter-
disciplinary, hepato-biliary outpatient clinic and the standard
assessment, which comprised of a clinical evaluation, liver
function tests, tumour markers detection tests and magnetic
resonance imaging [using the liver-specific contrast agent
Primovist© (from 2006 onwards (Bayer Schering Pharma AG,
Berlin, Germany)], had been carried out. An additional endo-
scopy/colonoscopy was performed in the majority of patients
to exclude a potential malignant origin of the liver lesions.
The symptoms were assessed before and 12 months after LR.
The assessment consisted of a questionnaire that was based on
a visual analogue scale to determine pain and discomfort
levels.
The indication for LR was given for every entity on the fol-
lowing basis: FNH – all symptomatic patients and patients
with risk factors such as growth dislodging other organs,
cholestasis, compression of vessels, or a significant increase in
tumour size during the observation period; for haemangioma –
all symptomatic patients, patients with tumours larger than
5 cm with a significant increase in size during the follow-up
and patients with signs of acute bleeding and no possibility of
control by interventional radiology; for HCA – symptomatic
patients independent from the size, patients with tumours lar-
ger than 5 cm, patients with an increase in size after discontin-
ued use of oral contraceptives, patients with suspected
malignant features on imaging, patients with histologically
proven ß-catenin-mutated adenoma independent from the size
owing to the significant risk of malignant transformation and
patients with histological atypia.5 Furthermore, patients with
unclear imaging results and no clear histology after biopsy
were resected (Table 1).
Transection of the liver parenchyma was performed as
recently described by our group.6–8
Given that laparoscopic LR was established in the Depart-
ment of General, Visceral, and Transplant Surgery in 2011, the
procedure was performed in patients with small, single and
well-accessible tumours. An LR of three or more Couinaud0s
Table 1 Treatment of benign liver lesions
HCA: biopsy all
Resection
All symptomatic after exclusion of other reasons for symptoms
All > 5 cm
All male patients – higher risk of transformation
All ß-catenin mutated
<5 cm if evidence of
Pathological atypia
Growth after stopping oral contraceptives
Suspected malignant features on imaging
FNH: biopsy all with atypical imaging features and / or significant
growth during observation
Resection
All symptomatic patients
Patients with risk factors such as growth dislodging other organs,
cholestasis, compression of vessels or significant increase in size
during the observation period
Haemangioma: no biopsy
Resection
All symptomatic patients
Patients with lesions >5 cm
Patients with significantly increasing size during the follow-up
Patients with signs of acute bleeding and no possibility of control
by interventional radiology
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segments was classified as a major resection. No cell saver was
used in the reported patients. According to the institutional
multidisciplinary standard operating procedures, in otherwise
healthy patients without any cardiovascular disease, a haemo-
globin of 5.5 mg/dl is accepted without substitution of blood
products as long as they are not symptomatic. Surgical compli-
cations were graded according to the Clavien–Dindo classifica-
tion.9–12 Patients who did not undergo a resection after initial
presentation were seen on a regular basis every 6 to 12 months
for follow-up and an indication for LR was given when the
lesion’s size increased or lesion-related symptoms developed.
Statistical analysis
The SAS software (Release 9.1, SAS Institute, Inc. Cary, NC,
USA) was used for statistical analysis. The quantitative vari-
ables were expressed as the median with an interquartile range
(IQR) or range. The Mann–Whitney U-test was used to com-
pare a laparoscopic and an open liver resection. Two-sided P-
values were always computed, and a difference was considered
statistically significant at P ≤ 0.05.
Results
Patients’ characteristics
Seventy-nine consecutive patients who underwent LR for
benign, solid liver lesions were identified from the institutional
LR database. Of the latter, 71 were female (90%), and the
median age of the total cohort was 40.6 years. One patient with
haemangioma was resected under emergency conditions for
spontaneous rupture of the lesion. The final histopathological
evaluation confirmed the diagnosis of FNH in 38 patients
(48%), haemangioma in 23 patients (29%) and HCA in 18
patients (23%). There was a significant difference in tumour size
at the time of resection among the tumour entities [FNH median
maximal tumour size was 6 cm (range 1–13 cm), haemangioma
median maximal size was 11 cm (range 1–23 cm) and HCA had
a median size of 7 cm (range 5–16 cm); P = 0.010]. Single
lesions were found in 42 patients (53%), 2–10 lesions in 32
patients (41%) and more than 10 lesions in five patients (n = 3
haemangiomatosis, n = 2 adenomatosis). Eleven patients (14%)
underwent a biopsy of the lesion before resection owing to
unclear imaging results. Transarterial embolization was per-
formed in four cases (n = 1 ruptured FNH and n = 3 haeman-
gioma) for bleeding before LR (Table 2).
Liver resection
The median time between diagnosis and resection was
43 months for FNH, 22 months for haemangioma and
3 months for HCA. Thirty-eight patients (48%) were resected
within 3 months after a presentation from their GPs as they
fulfilled our resection criteria at the time of presentation. The
other patients were resected owing to an increasing size of the
lesion, when patients became more symptomatic, or when
bleeding was evident in imaging studies (Table 3).
A major LR was performed in 23 patients (29% of the entire
group) and a minor hepatic resection in 56 patients (71%). A
laparoscopic LR was performed in nine patients (11% of the
group; all atypical resection). Of those, the median tumour
number was one lesion (with a range of 1–3 lesions) and the
median tumour size was 8 cm (with a range of 2–10 cm). Both
the median blood loss (laparoscopic resection 170 ml versus
open resection 660 ml) and the post-operative hospital stay
(laparoscopic resection 6 days versus open resection 9 days)
were significantly lower compared with an open resection
(P = 0.050; P = 0.010).
While there was no mortality after LR, the post-operative
30-day morbidity rate was 13.9% (n = 11). According to the
Clavien–Dindo classification, a Grade II complication occurred
in six patients, Grade IIIa occurred in four patients in whom
drainage of a pleural effusion was necessary and a Grade IIIb
Table 2 Characteristics of 79 patients with benign solid liver
lesions undergoing a liver resection
Total
cohort
n = 79
FNH
n = 38
(n = 4 male)
Haemangioma
n = 23
(n = 4 male)
HCA
n = 18
Gender n (%)
Male 8 (10) 4 (11) 4 (17) –
Female 71 (90) 34 (89) 19 (83) 18 (100)
Age, years
median (IQR)
40.6 (16.0) 42 (17.5) 45 (16.0) 36 (14.5)
Size, cm
median (IQR)
7.6 (5.0) 6.5 (4.5) 10.0 (6) 6.5 (5.0)
Oral
contraceptives
n (%)
56 (71) 24 (65) 16 (70) 16 (88)
ASA score n (%)
ASA 1 9 (11) 5 (13) 2 (9) 2 (11)
ASA 2 64 (81) 32 (84) 17 (74) 15 (83)
ASA 3 6 (8) 1 (3) 4 (17) 1 (6)
BMI, kg/m2
median (IQR)
25.5 (7.5) 24 (7.5) 25 (6.0) 28 (9.5)
Number of lesions n (%)
Singular 42 (54) 24 (63) 9 (39) 9 (50)
2–3 25 (32) 13 (35) 9 (39) 4 (22)
3–9 6 (8) 1 (2) 2 (9) 3 (16)
≥10 5 (6) – 3 (13) 2 (11)
Location n (%)
Left liver
(Seg 2/3 + 4)
26 (33) 11 (29) 7 (30) 8 (44)
Right liver
(Seg 5–8)
38 (48) 22 (58) 9 (39) 7 (39)
Both 15 (19) 5 (13) 7 (31) 3 (17)
FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma; BMI,
body mass index; ASA, American Society of Anesthesiologists; IQR,
interquartile range.
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complication in one patient in whom a surgical revision as a
result of acute bleeding was performed. Surgical re-intervention
was necessary for five patients owing to an incisional hernia
more than 1 year after the resection. Three of those patients
had a wound infection with prolonged wound healing after the
first operation.
The suspected histology was confirmed in 66 patients (84%).
In three patients with suspected HCA, final histo-pathological
evaluation showed FNH in two and haemangioma in the other
patient. In patients with unclear imaging results and pre-opera-
tive biopsy, the final histo-pathological evaluation revealed
FNH in six and HCA in three patients. In total, HCA was clas-
sified after histo-pathological evaluation as HNF1A-inactivated
subtype in two patients and an inflammatory subtype in 16
patients. There was no malignant transformation detectable in
any patient.
Outcome
After a median follow-up of 64 months, 75 patients were alive;
three patients died as a result of a malignant disease that was
not related to the liver lesion, and one patient committed sui-
cide. No patient developed recurrent disease. No further surgi-
cal intervention was needed during the follow-up period for
the patients with ≥ 10 haemangioma and the patients with
adenomatosis.
Pre-operative symptoms were found in 54 patients. Overall,
the symptoms were heterogenous with abdominal pain, a
feeling of unspecific abdominal pressure, nausea and fatigue
as mentioned by the majority of patients. Forty patients
reported a worsening of the symptoms within 1 year prior to
the LR. The incidence of symptoms increased with the size
of the lesion; 38% of patients with tumours larger than 5 cm
and 67% of patients with tumours larger than 10 cm com-
plained about abdominal pain and a feeling of unspecific
pressure (P = 0.075). Twenty-five patients (32%) were
asymptomatic at the time of the LR. Complete or partial
relief of symptoms was reported by 47 patients (87%) after
LR; however, 10 patients (19%) reported persistent impair-
ment of their daily activities after surgery. The majority of
them had abdominal pain, followed by digestive symptoms,
and paraesthesia of the abdominal scar. Patients with post-
operative complications after the LR had more post-operative
symptoms [medium visual analogue scale (VAS) score 6]
compared with those without complications (medium VAS
score 4) (P = 0.002; Table 4).
Discussion
The presented data clearly shows that resection of benign
lesions can be performed safely in well-selected patients with-
out mortality and with low post-operative morbidity. Further-
more, a total or partial relief of the symptoms can be achieved
in the majority of the patients.
This has clear implications for the management of patients
with benign liver tumours. In general, LR is commonly dis-
cussed in one of the two following scenarios: first, as an
already known and observed benign liver lesion with an
increase in size with or without clinical symptoms and second,
as a new, incidentally detected liver lesion with diagnostic
uncertainty.
The evidence for LR or interventional treatment of benign,
solid liver lesions is variable as randomized, controlled clinical
trials are pending. Apart from HCA, clear guidelines for the
clinical management have not been established, thus the treat-
ment of these patients is based on the clinical experience of
the responsible centre and the indication for LR is often an
individualized decision.13–16
Herein, we have proposed a treatment algorithm for patients
with benign, solid liver lesions based on the experience gained
treating the reported patients and retrospective studies as well
Table 3 Type of resection and outcome in 79 patients with benign solid liver lesions
Total cohort
n = 79
FNH
n = 38 (n = 4 male)
Haemangioma
n = 23 (n = 4 male)
HCA n = 18
Resection n (%)
Open 70 (88) 31 (81) 22 (95.6) 17 (94)
Laparoscopic 9 (12) 7 (19) 1 (4.4) 1 (5.3)
Hepatectomy right 18 (23) 10 (27) 2 (8.8) 6 (31.6)
Hepatectomy left 5 (6) 3 (8) – 2 (10.5)
Atypical resection 53 (67) 25 (65) 21 (91.2) 10 (55)
Blood loss; median (range) 325 (20–4000) 670 (20–4000) 600 (10–2000) 370 (200–800)
Intermediate care unit stay;
days median (range)
1 (1–9) 2 (2–9) 2 (2–4) 2 (2–4)
Hospital stay days; median (range) 8 (4–32) 8 (4–18) 12 (6–32) 8 (5–10)
Mortality rate – – – –
FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma.
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as case reports.4,5,17 Before a resection, the different treatment
options, including repetitive imaging to observe for a lesional
change, biopsy, conservative management and LR techniques,
are discussed with the patient to follow the principles of
informed consent. Nevertheless, the optimal time to perform a
resection is under debate.
In the present study, the time from diagnosis to resection
was significantly longer in patients with FNH compared with
patients with haemangioma and HCA, especially in the latter
the risk of potential malignant transformation might lead to a
more aggressive indication for LR than in the other entities.18
In the authors’ institution, the indication for resection of HCA
has been frequently made in recent years because the knowl-
edge about this entity has increased dramatically.15,16 There is
considerable controversy with respect to the absolute indica-
tion for LR in male patients with HCA, independent of the
size. Based on studies that reported an increased risk of early
HCC mimicking HCA in male patients, all male patients pre-
senting with suspected HCA were resected.19
Patients with large heamangiomas have been included in this
series because they represent a small proportion of individuals
who have been encouraged by their referring GP to seek the
medical council of a hepato-biliary specialist. Many patients
with haemangioma that was incidentally detected were diag-
nosed and treated without specialist consultation. The recom-
mendations for the treatment of haemangioma are similarly
heterogeneous as for FNH.20 The vast majority of patients with
hepatic haemangiomas do not require an LR; however, patients
with big lesions and a sub-capsular location have to be
informed about the risk of bleeding complications. Trans-arte-
rial embolization (TAE) was usually applied in patients with
signs of bleeding as part of the multidisciplinary treatment
approach to allow elective surgery. With this strategy, only one
patient needed to be resected as an emergency case owing to a
fulminant rupture. However in some centres, TAE is used pre-
emptively as a pre-operative intervention to reduce the risk of
bleeding or for downsizing lesions with borderline resectabil-
ity.21
Indeed, most of benign liver lesions are amenable to parench-
yma-sparing resection techniques. LR in well-selected patients
can be performed without mortality, as shown in the present ser-
ies; however, deaths after the resection of benign lesions have
been reported.22 Previously, Erdogan et al. showed that LR for
benign liver lesions is also associated with a lower morbidity
compared with resections for malignancies owing to a smaller
resection volume and very meticulous patient selection.23 This is
in line with the findings of the present study. The morbidity
rates of the present analysis are significantly lower compared
with resections for primary liver tumours or liver metastases in
the present centre.5,24–26 However, the groups cannot be com-
pared directly as the reported patient cohort is much younger,
without the background of chronic liver disease in most cases
and no history of pre-operative chemotherapy. About one-third
of the patients underwent a major LR. This was necessary owing
to the big tumour size and might reflect the impact of the late
presentation at our centre and the conservative observational
approach in asymptomatic lesions by many GPs. Nevertheless,
the 30-day morbidity rate was comparable between patients with
minor and major resections. As both HCA and FNH are hyper-
vascular tumours, considerable blood loss can happen during
the resection. The need for a blood transfusion is one of the
major concerns of many patients before the operation. However,
in the present series, no blood transfusions were needed. This is
a result of meticulous operation planning with 3-D simulation
of the resection plane and an operation technique using vascular
staplers for a parenchymal transection.27 With this approach, a
Pringle manoeuvre was not necessary for the reported patients.
Laparoscopic LR gains more and more influence in the
surgical management of benign liver lesions.28 The advantages
of an laparoscopic resection, such as the excellent post-opera-
tive recovery and the cosmetic results, predestines this tech-
nique for the treatment of benign lesions.29 In the present
study, patients undergoing laparoscopic LR had less blood loss
and a shorter time of stay compared with patients with an
open resection. This might be the result of selection bias, as
patients resected laparoscopically had fewer lesions and under-
went only minor resections. However, the indication for a
resection should be independent of the possibility for a laparo-
scopic approach and major laparoscopic LR should only be
performed by experienced specialists.30
Table 4 Effect on symptoms, based on complete questionnaires
from 54 patients
Total n = 54 Symptoms
Complete
release
n = 9 (17%)
Partial
release
n = 35 (65%)
Persistent
n = 10
(18%)
Tumour entity n (%)
FNH (n = 28) 6 (21) 17 (61) 5 (18)
Haemangioma (n = 19) 3 (16) 13 (69) 3 (16)
HCA (n = 7) – 5 (72) 2 (29)
Tumour size n (%)
5 cm (n = 15) 2 (13) 10 (67) 3 (20)
5–10 cm (n = 23) 5 (22) 14 (61) 4 (17)
>10 cm (n = 16) 2 (13) 11 (69) 3 (19)
Type of resection n (%)
Open (n = 46) 6 (13) 32 (70) 8 (18)
Laparoscopic (n = 8) 3 (38) 3 (38) 2 (25)
Major (n = 17) 2 (12) 7 (41) 8 (47)
Minor (n = 37) 7 (19) 28 (76) 2 (5)
Complication n (%)
Yes (n = 11) – 4 (36) 7 (64)
No (n = 43) 9 (21) 31 (72) 3 (7)
FNH, focal nodular hyperplasia; HCC, hepatocellular carcinoma.
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Clinical symptoms, which impair the daily life of the patients,
are one of the main reasons for a liver resection of benign, solid
tumours; to what extent these are the result of the diagnosed
lesions is difficult to verify. All other potential reasons for the
complaints have to be excluded before surgical treatment. The
high rates of resections in patients with FNH and haemangioma
are partially based on the symptomatic complaints of the
patients and their subjective fear of complications in big lesions.
In the present study, there was a correlation between lesion size
and symptom intensity. The resection of benign lesions resulted
in the total or partial relief of symptoms in the majority of the
patients in this trial. There was an overall improvement of the
general health status after a resection and a significant ameliora-
tion of the symptoms, which is in line with other published
reports.31 Patients with complications after the operation had
more persistent post-operative symptoms. The same was
reported by Miller et al., who showed that patients with compli-
cations have a deterioration of their quality of life at the onset.32
However, one has to note that some patients have persistent
complaints over a long time. Those patients were referred to the
chronic pain specialist team after exclusion of visceral reasons to
get the best support for their malady.
Conclusion
LR for benign, solid lesions can be performed safely in well-
selected patients without mortality and with a low post-opera-
tive morbidity. The significant reduction of symptoms is an
important part of the success of surgical treatment in these
patients. However, the management of benign, solid liver
lesions necessitates an individualized therapy within a multidis-
ciplinary, evidence-based, treatment algorithm.
Funding sources
None.
Conflict of interest
None declared.
References
1. Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D (2007)
Elective surgery for benign liver tumours. Cochrane Database Syst Rev:
CD005164.
2. Ehrl D, Rothaug K, Herzog P, Hofer B, Rau HG. (2012) “Incidentaloma”
of the liver: Management of a diagnostic and therapeutic dilemma. HPB
Surg 2012:891787.
3. Belghiti J, Pateron D, Panis Y, Vilgrain V, Flejou JF, Benhamou JP et al.
(1993)Resectionofpresumedbenign liver tumours.BrJSurg80:380–383.
4. Heiken JP. (2007) Distinguishing benign from malignant liver tumours.
Cancer Imaging 7 Spec No A:S1–S14.
5. Hoffmann K, Schemmer, P. (2011) Benigne solide Tumoren der Leber
aus chirurgischer Sicht. Allgemein- und Viszeralchirurgie up2date 1:1–
11.
6. Schemmer P, Friess H, Hinz U, Mehrabi A, Kraus TW, Z’graggen K
et al. (2006) Stapler hepatectomy is a safe dissection technique: analy-
sis of 300 patients. World J Surg 30:419–430.
7. Schemmer P, Bruns H, Weitz J, Schmidt J, B€uchler MW. (2008) Liver
transection using vascular stapler. HPB 10:249–252.
8. Schemmer P, Friess H, Dervenis C, Schmidt J, Weitz J, Uhl W et al.
(2007) Stapler hepatectomy – the use of endo GIA vascular staplers for
parenchymal transection. Dig Surg 24:300–305.
9. Dindo D, Demartines N, Clavien PA. (2004) Classification of surgical
complications: a new proposal with evaluation in a cohort of 6336
patients and results of a survey. Ann Surg 240:205–213.
10. Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L
et al. (2011) Bile leakage after hepatobiliary and pancreatic surgery: a
definition and grading of severity by the International Study Group of
Liver Surgery. Surgery 149:680–688.
11. Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M,
Adam R et al. (2011a) Posthepatectomy liver failure: a definition and
grading by the International Study Group of Liver Surgery (ISGLS). Sur-
gery 149:713–724.
12. Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ
et al. (2011b) Post-hepatectomy haemorrhage: a definition and grading
by the International Study Group of Liver Surgery (ISGLS). HPB 13:528–
535.
13. Belghiti J, Cauchy F, Paradis V, Vilgrain V. (2014) Diagnosis and man-
agement of solid benign liver lesions. Nat Rev Gastroenterol Hepatol
11:737–749.
14. Margonis GA, Ejaz A, Spolverato G, Rastegar N, Anders R, Kamel IR
et al. (2015) Benign solid tumors of the liver: management in the mod-
ern era. J Gastrointest Surg 19:1157–1168.
15. Blanc JF, Frulio N, Chiche L, Sempoux C, Annet L, Hubert C et al.
(2015) Hepatocellular adenoma management: call for shared guidelines
and multidisciplinary approach. Clin Res Hepatol Gastroenterol 39:180–
187.
16. Sempoux C, Chang C, Gouw A, Chiche L, Zucman-Rossi J, Balabaud
C et al. (2013) Benign hepatocellular nodules: what have we learned
using the patho-molecular classification. Clin Res Hepatol Gastroenterol
37:322–327.
17. Kim J, Ahmad SA, Lowy AM, Buell JF, Pennington LJ, Moulton JS et al.
(2004) An algorithm for the accurate identification of benign liver
lesions. Am J Surg 187:274–279.
18. Karkar AM, Tang LH, Kashikar ND, Gonen M, Solomon SB, DeMatteo
RP et al. (2013) Management of hepatocellular adenoma: comparison
of resection, embolization and observation. HPB 15:235–243.
19. Ronald M, Woodfield J, McCall J, Koea J. (2004) Hepatic adenomas in
male patients. HPB 6:25–27.
20. Koea JB. (2013) Hepatic incidentaloma: the rule of tens. HPB 15:379–
383.
21. Chen RC, Lii JM, Chen WT, Tu HY, Chiang LC. (2006) Transcatheter
arterial chemoembolization in patients with hepatocellular carcinoma
and coexisting hepatic cavernous hemangioma. Eur Radiol 16:1346–
1350.
22. Sesto ME, Vogt DP, Hermann RE. (1987) Hepatic resection in 128
patients: a 24-year experience. Surgery 102:846–851.
23. Erdogan D, Busch OR, Gouma DJ, Van Gulik TM. (2009) Morbidity and
mortality after liver resection for benign and malignant hepatobiliary
lesions. Liver Int 29:175–180.
HPB 2015, 17, 994–1000 ª 2015 International Hepato-Pancreato-Biliary Association
HPB 999
24. Hoffmann K, Muller-Butow V, Franz C, Hinz U, Longerich T, Buchler
MW et al. (2014) Factors predictive of survival after stapler hepatectomy
of hepatocellular carcinoma: a multivariate, single-center analysis. Anti-
cancer Res 34:767–776.
25. Hoffmann K, Franz C, Hinz U, Schirmacher P, Herfarth C, Eichbaum M
et al. (2010) Liver resection for multimodal treatment of breast cancer
metastases: identification of prognostic factors. Ann Surg Oncol
17:1546–1554.
26. Hoffmann K, Luible S, Hinz U, B€uchler MW, Schemmer P. (2015) Impact
of portal vein resection on oncological long-term outcome in patients
with hilar cholangiocarcinoma. Surgery pii: S0039-6060(15)00361-X. in
press.
27. Fischer L, Hoffmann K, Neumann JO, Sch€obinger M, Grenacher L,
Radeleff B et al. (2007) The impact of 3d operating planning on liver
surgery. Imaging Decisions 1:39–44.
28. Toro A, Gagner M, Di Carlo, I. (2013) Has laparoscopy increased surgi-
cal indications for benign tumors of the liver? Langenbecks Arch Surg
398:195–210.
29. Dokmak S, Raut V, Aussilhou B, Fteriche FS, Farges O, Sauvanet A
et al. (2014) Laparoscopic left lateral resection is the gold standard for
benign liver lesions: a case-control study. HPB 16:183–187.
30. Schon MR. (2010) [Value of laparoscopic liver resection]. Chirurg
81:516–525.
31. Kamphues C, Engel S, Denecke T, Bova R, Hippler-Benscheidt M, Puhl G
et al. (2011) Safety of liver resection and effect on quality of life in patients
with benign hepatic disease: single center experience. BMC Surg 11:16.
32. Miller AR, St Hill CR, Ellis SF, Martin RC. (2013) Health-related quality
of life changes following major and minor hepatic resection: the
impact of complications and postoperative anemia. Am J Surg
206:443–450.
HPB 2015, 17, 994–1000 ª 2015 International Hepato-Pancreato-Biliary Association
1000 HPB
